Peer-reviewedCC BY-NC 4.0Hematological Oncology
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort
Abstract
Although clinical trials showed outcomes improvement in MCL, their applicability to real-world practice remains limited. Using the prospective REALYSA registry (NCT03869619), we evaluated contemporary management, highlighting evolving practices and differences by age. Among 295 patients, 63% were ≥ 65 years, 48% had a high-risk MIPI score with Ki-67 ≥ 30% in 53% and aggressive morphology in 11%. Younger patients received high-dose cytarabine (93%) and ASCT (78%). Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%). Two-year event-free (EFS-2y) and overall (OS-2y) survivals were 80% and 89% in < 65y; 60% and 77% in ≥ 65y. Among 238 patients responders after induction,
Related
- Morphologic intratumoral heterogeneity from routine whole-slide histopathology is prognostic for survival in primary central nervous system lymphoma: development in the LOC Network and international external validation
- Association of BTRC rs10883617 with Survival Outcomes in Surgically Resected Non-Small Cell Lung Cancer
- Long-term multidimensional outcomes of China’s national cochlear implant assistance programme over twenty-one years
- Initial treatment patterns and survival in biliary tract cancer: A retrospective cohort study in Kyoto, Japan
- Estimating marginal association between paired outcomes in clustered data with an application to analyzing caries and periodontal disease data from the National Health and Nutrition Examination Survey
BibTeX
@article{cheminant2026contemporary,
title = {{Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort}},
author = {Morgane Cheminant and Patrick Fogarty and Sylvain Carras and Clémentine Sarkozy and Cédric Rossi and Luc Fornecker and Bijou Fontanet and Adrien Chauchet and Sandra Leguyader‐peyrou and Laure Lebras and Lucie Oberic and Loïc Ysebaert and Ghandi Damaj and Gaelle Labouré and Ludovic Fouillet and Stéphanie Guidez and François Lemonnier and Krimo Bouabdallah and Thomas Gastinne and Nadine Morineau and Sandy Amorim and Fabrice Jardin and Julie Abraham and Roch Houot and Catherine Thieblemont and Franck Morschhauser and Rémy Gressin and Steven Le Gouill and Olivier Hermine and Fanny Cherblanc and Alain Monnereau and Aurélien Belot and Hervé Ghesquieres and Benoit Tessoulin},
journal = {Hematological Oncology},
year = {2026},
month = oct,
doi = {10.1002/hon.70264},
url = {https://u-bordeaux.hal.science/hal-05786298v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real‐World Analysis From REALYSA, a LYSA Cohort
AU - Morgane Cheminant
AU - Patrick Fogarty
AU - Sylvain Carras
AU - Clémentine Sarkozy
AU - Cédric Rossi
AU - Luc Fornecker
AU - Bijou Fontanet
AU - Adrien Chauchet
AU - Sandra Leguyader‐peyrou
AU - Laure Lebras
AU - Lucie Oberic
AU - Loïc Ysebaert
AU - Ghandi Damaj
AU - Gaelle Labouré
AU - Ludovic Fouillet
AU - Stéphanie Guidez
AU - François Lemonnier
AU - Krimo Bouabdallah
AU - Thomas Gastinne
AU - Nadine Morineau
AU - Sandy Amorim
AU - Fabrice Jardin
AU - Julie Abraham
AU - Roch Houot
AU - Catherine Thieblemont
AU - Franck Morschhauser
AU - Rémy Gressin
AU - Steven Le Gouill
AU - Olivier Hermine
AU - Fanny Cherblanc
AU - Alain Monnereau
AU - Aurélien Belot
AU - Hervé Ghesquieres
AU - Benoit Tessoulin
PY - 2026
DA - 2026/10/08
JO - Hematological Oncology
DO - 10.1002/hon.70264
UR - https://u-bordeaux.hal.science/hal-05786298v1
AB - Although clinical trials showed outcomes improvement in MCL, their applicability to real-world practice remains limited. Using the prospective REALYSA registry (NCT03869619), we evaluated contemporary management, highlighting evolving practices and differences by age. Among 295 patients, 63% were ≥ 65 years, 48% had a high-risk MIPI score with Ki-67 ≥ 30% in 53% and aggressive morphology in 11%. Younger patients received high-dose cytarabine (93%) and ASCT (78%). Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%). Two-year event-free (EFS-2y) and overall (OS-2y) survivals were 80% and 89% in < 65y; 60% and 77% in ≥ 65y. Among 238 patients responders after induction,
SN - 0278-0232
SN - 1099-1069
ER -